PJWCreative, Author at HighField Bio

June 13, 2023 in HighField in the News

Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

PJWCreative 0 Like Post 0 Comment

Click here

June 13, 2023 in Press Release

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

PJWCreative 0 Like Post Comments Off

The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugatesHANGZHOU, China--June 13, 2023--HighField Biopharmaceutical ...

May 31, 2023 in Press Release

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

PJWCreative 0 Like Post Comments Off

The abstract of preliminary data from a Phase 1a trial of HF1K16, which targets myeloid-derived suppressor cells (MDSCs), is published online at the 2023 ASCO Annual Meeting in Chicago, ILHANGZHOU, Ch ...

May 24, 2023 in References

Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection

PJWCreative 0 Like Post 0 Comment

April 3, 2023 in References

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

PJWCreative 0 Like Post 0 Comment

February 12, 2023 in Publications

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

PJWCreative 0 Like Post Comments Off

Click here

August 30, 2022 in Publications

mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

PJWCreative 0 Like Post Comments Off

Click here

August 30, 2022 in References

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

PJWCreative 0 Like Post 0 Comment

July 17, 2022 in References

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

PJWCreative 0 Like Post Comments Off

April 12, 2022 in Publications

Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment

PJWCreative 0 Like Post Comments Off

Click here

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment